Haemorrheological effects of prostaglandin E1 infusion in Raynaud's syndrome.
Eighteen patients with severe Raynaud's syndrome had impaired deformability of erythrocytes, as measured by filtration through 5 micron diameter pores, compared with 19 healthy controls. The patients were given prostaglandin E1 (PGE1) or placebo by intravenous infusion for 72 h to assess the haemorrheological action of PGE1. Contrary to a previous report, PGE1 did not improve erythrocyte filterability. Infusion of PGE1 did, however, evoke an acute phase response with hyperproteinaemia and a leucocytosis and is a potentially important mediator of this stress response in patients with vascular disease.
D000328:Adult; D000368:Aged; D000527:Alprostadil; D001809:Blood Viscosity / Q000187:drug effects; D002097:C-Reactive Protein / Q000097:blood; D004912:Erythrocytes / Q000502:physiology; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D008875:Middle Aged; D011458:Prostaglandins E / Q000627:therapeutic use*; D011897:Random Allocation; D011928:Raynaud Disease / Q000097:blood* / Q000188:drug therapy
D011458:Prostaglandins E; D005340:Fibrinogen; D002097:C-Reactive Protein; D000527:Alprostadil